The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Primary analysis of INDEPENDENCE: luspatercept in transfusion-dependent patients with MF on a JAKi
Francesco Passamonti, MD, University of Milan, Milan, Italy, presents the safety and efficacy findings from the primary analysis of the Phase III INDEPENDENCE trial (NCT04717414), which investigated luspatercept in patients with myelofibrosis (MF) receiving a JAK inhibitor (JAKi) and requiring red blood cell transfusions. Prof. Passamonti notes that the study did not meet its primary endpoint and discusses why this may have occurred, highlighting the unexpectedly high response rate in the placebo cohort in the Asian Pacific region. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
